Although the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
Just because the Oncology Care Model (OCM) is ending June 30, 2022, it does not mean practices can turn back the clock and revert to how they provided care prior to the OCM, explained Debra Patt, MD, PhD, MBA, executive vice president of Texas Oncology.
On June 27, the Biden administration announced the new model that will replace OCM. The Enhancing Oncology Model will begin in July 2023.
Transcript
What do you expect practices will have to change with the OCM ending and a gap before the next model starts?
It is a challenge that OCM is scheduled to end here in June of 2022. We do anticipate that CMMI [Center for Medicare and Medicaid Innovation] will come out with either an OCM extension or a new model, the Oncology Care First model. I will say that the paradigm of cancer care has changed. We have made—and by we, I say Texas Oncology, have made—tens of millions of dollars of investments in infrastructure resources to deliver better cancer care.
Now, the findings of the specifics of OCM and the infrastructure investments that we’ve had is just how we deliver care today. And so, it’s almost impossible for me to think about divesting resources or changing the expectations of the level of care.
When we implemented OCM for our patient population, it wasn’t just for OCM patients. We made these changes for all of the patients at Texas Oncology. So, it’s hard to see going back. I do hope that CMMI comes to us with new innovative models that build upon what we’ve learned from OCM, because I think it’s better care for patients.
Balancing Cost and Quality in Oncology: A Value-Based Care Perspective
January 30th 2025Travis Brewer, vice president of payer and public health strategy/relations at Texas Oncology, shared that value-based oncology care can achieve both cost efficiency and high-quality outcomes through integrated multidisciplinary teams, flexible payment models, and targeted treatment approaches.
Read More
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
Unlocking Access: Exploring Mental Health Care Among Medicaid Managed Care Enrollees
January 23rd 2025On this episode of Managed Care Cast, we speak with the author of a study published in the January 2025 issue of The American Journal of Managed Care® to examine the association between quantitative network adequacy standards and mental health care access among adult Medicaid enrollees.
Listen